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Abstract Appropriate placental function is essential for successful pregnancy and placental dysfunction is associated 
with fetal growth restriction (FGR) and stillbirth. Villitis of unknown etiology (VUE) and chronic intervillositis of unknown 
etiology (CIUE) are immune-mediated conditions characterized by placental infiltrates of macrophages, CD4 and CD8 T 
cells. VUE and CIUE occur more frequently in the placentas of pregnancies complicated by FGR. The mechanisms by 
which this inflammation induces placental dysfunction are yet to be defined. We aimed to develop an in vitro model of 
placental inflammation to investigate functional consequences of immune cells in the placental environment. Fragments 
of placental tissue were co-cultured with CD4 and CD8 T cells isolated from whole blood. CellTrackerTM fluorescence was 
used to identify T cells in cultured explants. Tissue histology, endocrine and nutrient transport function was assessed using 
established methods. This novel preparation will enable future investigations into immune cell interactions with placenta.
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INTRODUCTION
The placenta is critical to successful pregnancy, forming the mater-
nal-fetal interface that supplies nutrients and oxygen to support fetal 
growth and removes waste products of fetal metabolism whilst main-
taining a distinct barrier between mother and fetus [1]. If the placenta 
fails to function adequately there are serious health implications for the 
fetus, including an increased risk of fetal growth restriction (FGR) and 
stillbirth [2-5]. There is increasing evidence that sterile inflammation has 
a role in the placental dysfunction underlying these pregnancy compli-
cations. Villitis of unknown etiology (VUE) and chronic intervillositis 
of unknown etiology (CIUE) are specific inflammatory conditions of 
the placenta associated with FGR that may also be linked to stillbirth 
[6]. In the majority of cases of VUE and CIUE, an underlying clinical 
infection cannot be detected [7,8]. VUE is characterized by migration 
of CD4 and CD8 T cells from maternal blood into the stroma of the 
villi, the functional units of the human placenta and has been well 
characterized in morphological studies [9-13]. In CIUE maternal mac-
rophages, CD4 and CD8 T cells accumulate in the intervillous space 
[14]. In addition to a characteristic cellular phenotype of VUE lesions, 
increases in pro-inflammatory cytokines interleukin (IL)-2 and IL-12 
and a decrease in the anti-inflammatory cytokine IL-4 have been de-
scribed in lesions [15]. Upregulation of pro-inflammatory chemokine 
mRNA has also been reported in VUE lesions [16]. It is probable that 
migrating T cells alter intravillous cytokine levels which may dysreg-
ulate placental development or function leading to increased risk of 
fetal harm. However, these effects have not been explored using human 
placenta as VUE cannot be detected antenatally. The only way to study 
the effects of leukocyte infiltration is by developing an in vitro model 
of maternal immune cell infiltration into placental tissue and examining 
the functional consequences. 
Previous models of placental inflammation have utilized lipopoly-
saccharide (LPS) as a stimulator of the immune response, which mimics 
infectious etiology, as opposed to the sterile inflammation of VUE and 
CIUE [17]. Therefore, we aimed to develop an in vitro model of VUE/
CIUE to enable investigations into the effect of CD4 and CD8 cell 
infiltration into the intervillous space and villous stroma on placental 
function. There is an established method of placental explant culture in 
which villous tissue fragments are dissected from term placental tissue 
and maintained in culture for 7–11 days [18]. The morphological, endo-
crine and functional characteristics of these cultures are well established 
and explants have been used extensively since 2001 to investigate the 
effects of long term (days) interventions on placental cell turnover, 
endocrinology and nutrient transport function [5,19-21]. T cells can 
be isolated from whole blood [22] and intracellular fluorescence can 
be introduced to enable cell tracking [23]. Therefore, we explored the 
possibility that T cells isolated from whole blood could be co-cultured 
with placental explants and would be visible in the intervillous space 
(mimicking CIUE) and in the villous stroma following migration into 
the tissue (mimicking the lesions in VUE). 
A unique feature of placental explant culture is that the syncytiotro-
phoblast (STB), the continuous layer of highly specialized nutrient 
transporting epithelium that covers the villous tissue, partially detaches 
in the first 1–2 days of culture and then regenerates over the course of 
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5–7 days to form a new STB thereafter [18]. An intact STB layer acts 
as a barrier to cells migrating from the intervillous space to the villous 
tissue. We aimed to accelerate this process in order to conform to a 
culture period of 4 days; the optimal time that T cells can be sustained 
in vitro [24]. We proposed that mild trypsinization for 15 min prior 
to commencing the culture would promote STB detachment without 
complete denudation of the underlying cytotrophoblasts and stromal 
tissue and encourage the passage of T cells into the tissue. A previous 
study that trypsinized first trimester placental tissue reported no effect 
on the viability of the tissue in culture [20]. We also examined whether 
the function of the explants was influenced by culturing them in the 
presence of cytokines required to maintain T cells in vitro. Endpoints 
were chosen to assess the effect of experimental procedures on key as-
pects of placental function performed by STB. Histological analysis of 
tissue sections stained for the cytoskeletal protein cytokeratin 7 (CK7) 
confirmed the integrity of STB. Endocrine function was investigated 
by measuring release of human chorionic gonadotrophin (hCG). This 
hormone is produced by differentiated STB in situ, promotes trophoblast 
cell fusion and stimulates progesterone production [1,25]. hCG is used 
as a marker of syncytialization and STB viability [26]. Its production 
is maximal in early pregnancy, but rises again in late pregnancy and is 
predominantly secreted into the maternal circulation [1]. Typically in 
explants, hCG release drops at day 1 of culture, gradually increasing 
from day 2 until a plateau is reached at around day 5 of culture [18]. 
Nutrient transport was assessed by measuring the activity of the system A 
amino acid transporter. This transporter is situated in the maternal facing 
membrane of STB and transfers amino acids (alanine, glycine, serine) 
to the fetus. System A is a well characterized sodium-dependent amino 
acid transporter whose activity can be determined by measuring tissue 
accumulation of the radiolabeled non-metabolized amino acid analogue 
14Cmethylaminoisobutyric acid (MeAIB) [19,27]. System A activity 
in placental villous explants has been measured previously [19] and is 
known to be reduced in FGR [5,21,28]. The sodium-dependent uptake 
of 14C MeAIB into villous explants was used to determine system A 
activity [19]. Here we describe the results of validation experiments 
that have established a novel protocol for placental explant co-culture 
with isolated, traceable CD4 and CD8 T cells (Fig. 1).
Figure 1. Schematic representation of the timeline and steps involved in the process of explant and T cell co-culture. 
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MATERIALS AND METHODS
Materials
All reagents supplied by Sigma-Aldrich (Dorset, UK) unless oth-
erwise stated.
 9 RPMI-1640 medium (Cat. # 21875, Gibco, UK) supplemented 
with:
• 5% Fetal bovine serum (FBS) (Gibco, UK)
• Insulin solution 1 µg/ml
• Streptomycin sulphate 100 µg/ml
• Penicillin G 100 IU/ml
• Retinol acetate 0.1 µg/ml
• Calcium chloride
• L-alanine 25 µg/ml
• L-cysteine 200 µg/ml
• Ascorbic acid 50 µg/ml
 9 Sterile PBS with Ca2+ and Mg2+
 9 Sterile PBS without Ca2+ and Mg2+
 9 70% ethanol
 9 0.01% trypsin in sterile PBS
 9 LymphoprepTM (Cat. # 07801, Stem Cell Technologies, UK)
 9 EasySepTM buffer (Stem Cell Technologies, UK)
 9 EasySepTM CD8 T cell isolation kit, positive selection (Cat. # 
18013, Stem Cell Technologies, UK)
 9 EasySepTM CD4 T cell enrichment kit, negative selection (Cat. # 
19012, Stem Cell Technologies, UK)
 9 Recombinant human (rh) interleukin (IL)-2 10 ng/ml (Life Tech-
nologies, UK)
 9 RhIL-15 10 ng/ml (Life Technologies, UK)
 9 Anti-CD3 antibody 5 µg/ml (BD Pharmingen, UK)
 9 Anti-CD28 antibody 1 µg/ml (BD Pharmingen, UK)
 9 CellTrackerTM CMPTX red dye (Life Technologies, UK)
 9 CellTrackerTM CMFDA green dye (Life Technologies, UK)
Equipment
 9 Sterile Petri dishes
 9 24-well culture plates
 9 12-well culture plates
 9 Sterile Pasteur pipettes
 9 SepMate centrifugation tubes (Stem Cell Technologies, UK)
 9 15 ml and 50 ml centrifuge tubes
 9 5 ml Eppendorf tubes
 9 5 ml, 10 ml and 25 ml sterile stripettes
 9 5 ml round-bottomed polystyrene falcon tubes
 9 Sterile dissecting scissors and forceps
 9 Centrifuge (Beckman Coulter)
 9 EasySepTM magnet (Stem Cell Technologies, UK)
 9 Humidified incubator 37°C, 21% O2, 5% CO2
 9 Laminar air flow
 9 Inverted microscope (Olympus CK2, Olympus, Southend-on-Sea, 
UK)
 9 Fluorescent microscope (Zeiss Observer Z1 AX10, Zeiss, Welwyn 
Garden City, UK)
 9 Flow cytometer (BD Accuri C6, BD Biosciences, Oxford, UK)
Placentas and blood
Term (37–42 week) placentas were obtained within 30 min of deliv-
ery from women with uncomplicated pregnancies undergoing elective 
caesarean section. Tissue was donated with informed written consent in 
accordance with North West NHS REC approval (Ref: 08/H1010/55+5). 
Uncomplicated pregnancies were defined as maternal BMI < 30 and 
no evidence of pre-eclampsia, gestational diabetes mellitus or fetal 
growth restriction. Multiple pregnancies, fetal anomalies or abnormal 
fetal heart rate were also excluded. Blood samples used in establishing 
the model were taken from non-pregnant donors (10 ml) collected in 
lithium heparin tubes on day 0 of co-culture.
Trypsinization and syncytiotrophoblast morphology
Placental villous tissue samples were dissected, washed free of 
maternal blood and exposed to trypsin to accelerate STB detachment 
prior to culture. In initial trials, tissue was incubated in different concen-
trations of trypsin (0.01%–0.125%), over 5–30 min (n = 2 placentas). 
Following trypsin treatment, tissue was fixed in 4% neutral buffered 
formalin (NBF) and the effect of trypsinization on STB detachment was 
confirmed by examination of immunohistochemistry (IHC) to detect 
cytokeratin 7, a cytoskeletal protein expressed by STB. A standardized 
laboratory protocol for immunostaining with colorimetric detection was 
followed, as described by Hamilton et al. [29]. Heat-mediated antigen 
retrieval with citrate buffer was performed and the primary antibody 
applied at 0.9 µg/ml. Each tissue section had a corresponding negative 
control on which mouse IgG (Sigma Aldrich, Dorset, UK) was applied 
at the same concentration as the primary antibody.
Trypsinization and placental function
Villous tissue was maintained in co-culture with T cells for 4 days, the 
optimal time for maintenance of these immune cells in culture. There-
fore, pilot experiments were performed to determine whether exposure 
to trypsin prior to culture affected STB integrity and function after 4 
days compared to non-trypsinized tissue. Villous tissue was exposed to 
0.01% trypsin at 37°C for 15 min, the trypsin aspirated and the tissue 
washed twice in RPMI 1640 medium (Gibco). Explants were cultured 
in a 24-well plate (3 explants per well) in RPMI 1640 medium for 96 
h. Culture medium was harvested daily for hCG analysis and explants 
fixed daily to assess STB morphology using CK7 staining as described 
above. At 96 h explants were fixed in 4% neutral buffered formalin 
(NBF) then embedded in paraffin wax prior to immunohistochemical 
staining to assess apoptosis, proliferation and syncytiotrophoblast 
(STB) regeneration using antibodies against caspase-3, Ki67 and CK7 
respectively using the method described above. Primary antibodies 
were applied at the following concentrations: CK7 0.9 µg/ml, Ki67 0.4 
µg/ml and caspase-3 1 µg/ml. System A activity was determined as the 
sodium-dependent uptake of 14C MeAIB. 
Trypsinization, cytokines and placental function
T cell activation, proliferation and survival, requires cytokines, 
specifically interleukin (IL)-2 and IL-15. This necessitates exposure of 
the explants to these cytokines during co-culture. To determine whether 
IL-2 and IL-15 alter nutrient transport, trypsinized and non-trypsinized 
tissue was cultured for 96 h in RPMI 1640 medium with or without 
IL-2 and IL-15 (both 10ng/ml) and system A activity was determined 
at the end of culture.
EasySep cell isolation
Initially, whole blood from a non-pregnant donor was used to evaluate 
the experimental protocol. The EasySep cell isolation system was used 
to isolate CD8 T cells by positive selection and CD4 cells by negative 
selection. The manufacturer’s standard protocol was followed. Briefly, 
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whole blood was centrifuged to separate out peripheral blood mono-
nuclear cells (PBMCs). PBMCs were then incubated with EasySep 
CD8 positive selection antibody before a secondary incubation with 
magnetic nanoparticles. The suspension was placed in a magnet to pull 
the CD8 cells to the side of the tube and the supernatant reserved for 
CD4 isolation. CD4 isolation involved incubation with an antibody 
cocktail to negatively select out unwanted cells and another incubation 
with magnetic particles. Once isolated, cells were counted and then 
plated at 1 × 106 cells/ml. The cells were transferred into a 12-well plate 
and activated via anti-CD3 coating of the wells and culture for 24 h in 
RPMI medium with anti-CD28 before being counted again. Control 
wells were uncoated and recombinant human cytokines IL-2 and IL-15 
were added to half of the wells.
T cell labeling
In order to identify immune cells in the intervillous space, and to 
ascertain whether T cells migrated into the villous tissue, CellTrackerTM 
tracing dyes (Life Technologies) were identified as candidates for visu-
alization of isolated cells. CellTrackerTM dyes are fluorescent markers 
that pass freely through the cell membrane becoming cell-impermeant 
reaction products. They are passed on to daughter cells, through 3–6 
generations yet are not transferred to adjacent, non-stained cells. Iso-
lated CD4 and CD8 T cells were cultured with CellTrackerTM Red 
CMPTX or CellTrackerTM Green CMFDA dyes respectively following 
the manufacturer’s protocol.
System A activity
To determine whether trypsinization and culture in RPMI medium 
with cytokines affected nutrient transport, system A activity was exam-
ined as the sodium dependent uptake of 14CMeAIB into the explants 
after 4 days of culture. 
hCG secretion
Conditioned culture medium was collected each day. Undiluted 
culture medium was assayed for hCG secretion by ELISA (DRG Di-
agnostics, Marburg, Germany) according to standard manufacturers’ 
protocol. Plates were read on a FLUOstar Omega microplate reader 
(BMG Labtech, Aylesbury, UK), values corrected for protein content 
and expressed as mIU/ml/mg protein.
PROCEDURE
Day 0 – preparation of anti-CD3 coated plates for cell culture
1. Prepare 4 ml sterile PBS supplemented with 5 µg/ml anti-CD3 antibody.
2. Add 1 ml antibody solution to 4 wells of a 12-well plate.
3. Incubate for 2 h at 37°C.
4. Wash twice with 1 ml sterile PBS.
NOTE: Coated plates can be prepared the day before they are required and stored at 4°C overnight instead of a 2-h 
incubation at 37°C on the day of isolation.
Day 0 – production of placental fragments for culture
5. Prepare 1 L RPMI-1640 medium supplemented with 5% fetal bovine serum (FBS), 1 µg/ml insulin, 100 µg/ml 
streptomycin sulphate, 100 IU/ml penicillin G, 0.1 µg/ml retinol acetate, 25 µg/ml L-alanine, 200 µg/ml L-cysteine 
and 50 µg/ml ascorbic acid. Filter prepared medium through 0.2 µm bottle top vacuum filter (Corning, Germany). 
6. Receive placenta within 30 min of delivery. Take four biopsies of approximately 1 cm3 from random areas of 
parenchyma, place in pre-warmed sterile PBS. All subsequent steps take place in the laminar flow hood.
7. Cut approximately 30 smaller fragments (~4–5 mm3) of villous tissue from each of the large biopsies, taking care 
to avoid fetal chorionic plate, decidua and large blood vessels. Transfer to sterile petri dishes with 10 ml pre-
warmed sterile PBS.
8. Wash twice in sterile PBS.
9. Transfer tissue fragments to an empty petri dish. Add 10 ml 0.01% trypsin, incubate at 37°C for 15 min.
10. Remove trypsin solution then neutralize with two changes of RPMI medium.
11. Add 1 ml RPMI medium to 16 wells of a 24 well culture dish and place three fragments in each
12. Culture for 24 h in a humidified incubator at 37°C, 21% O2.
Day 0 – T cell isolation from 10 ml whole blood
13. Add 15 ml Lymphoprep to a SepMate tube.
14. In a separate centrifuge tube, mix blood with an equal volume of EasySep buffer. Carefully transfer the blood/
buffer mix to the SepMate tube ensuring the tube is kept vertical.
15. Centrifuge at 1200 g for 10 min at room temperature with the brake on.
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16. Pour off the supernatant (which contains the peripheral blood mononuclear cells) into a new centrifuge tube; do 
not invert the SepMate tube for longer than two seconds. NOTE the tube that the supernatant is poured into does 
not have to be a SepMate tube. 
17. Centrifuge for 8 min at 300 g at RT. 
18. Remove supernatant with a stripette taking care not to disturb the pellet.
19. Add ~10 ml EasySep buffer and re-suspend the cells. Centrifuge for 8 min at 300 g at RT.
20. Repeat steps 6 and 7.
21. Remove supernatant and re-suspend cells in 4 ml EasySep buffer. Pour into a 5 ml round-bottomed falcon tube.
22. Centrifuge for 8 min at 300 g at RT, remove supernatant.
23. Re-suspend pellet with 100 µl EasySep buffer. Add 10 µl EasySep CD8 positive selection cocktail. Mix well and 
incubate for 15 min at RT.
24. Mix the magnetic nanoparticles by vigorous pipetting (do not vortex). Add 10 µl of magnetic nanoparticles. Mix 
well, incubate for 10 min at RT.
25. Bring the cell suspension to a total of 2500 µl using EasySep buffer. Mix by gentle pipetting. Place the tube in the 
magnet for 5 min ensuring that tube does not have the cap on.
26. Whilst the tube is still in the magnet invert it, pouring the supernatant into a new 5 ml falcon tube. Leave inverted 
for 2–3 seconds but do not shake or blot any drops. Save the pour off for the isolation of CD4 T cells.
27. Take the tube out of the magnet, add ~2500 µl EasySep buffer. Mix by gentle pipetting, place the tube back in the 
magnet and set aside for 5 min.
28. Whilst the tube is still in the magnet invert it, pouring off the supernatant. (There is no need to save this supernatant.)
29. Repeat steps 15 and 16.
30. Re-suspend in 2500 µl EasySep buffer, centrifuge for 8 min at 300 g at RT.
31. Remove supernatant, re-suspend in 2 ml RPMI medium with 1 µg/ml anti-CD28, 10 ng/ml rhIL-2 and 10 ng/ml 
rhIL-12.
32. Use the supernatant/first pour off from the CD8 selection, centrifuge for 8 min at 300 g at RT.
33. Remove the supernatant, re-suspend cells in 250 µl EasySep buffer.
34. Add 12.5 µl EasySep Human CD4 T cell enrichment cocktail. Mix well and incubate for 10 min at RT.
35. Vortex the D magnetic particles for 30 seconds. Add 25 µl magnetic particles, mix well and incubate for 5 min at RT.
36. Bring the cell suspension to 2500 µl by adding EasySep buffer (~2200 µl) and mix gently.
37. Place the tube, without cap, into the magnet for 5 min.
38. With the tube in the magnet, invert, pouring the supernatant into a new 5 ml tube. The cells are in the pour off.
39. Centrifuge for 8 min at 300 g at RT.
40. Remove supernatant, re-suspend in 2 ml RPMI medium with 1 µg/ml anti-CD28 to activate T cells, 10 ng/ml rhIL-2 
and 10 ng/ml rhIL-15 to stimulate proliferation of T cells.
41. Plate cells into the coated wells of a 12-well plate.
42. Incubate overnight in a humidified incubator at 37°C, 21% O2.
Day 1 – Introduction of CellTrackerTM fluorescence
43. Remove medium from wells, transferring into two 5 ml Eppendorfs (one for CD4 cells, one for CD8 cells).
44. Add 500 µl ice-cold sterile PBS (without Ca2+ and Mg2+), gently scrape the bottom of the wells to release the cells. 
Transfer to the Eppendorfs containing the medium.
45. Examine the plates on an inverted microscope to check how many cells remain attached.
46. Repeat step 2.
47. Centrifuge at 1300 rpm for 5 min at RT.
48. Dilute 1 µl CellTracker red in 1 ml pre-warmed RPMI medium and 1 µl CellTracker green in 1 ml pre-warmed 
RPMI medium.
49. After centrifugation, remove supernatant, re-suspend cells in pre-warmed medium with CellTracker (we used red 
for CD4 cells and green for CD8 cells). Incubate at 37°C for 45 min.
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50. Centrifuge at 1300 rpm for 5 min at RT.
51. Re-suspend in 1 ml pre-warmed medium. Incubate at 37°C for 30 min.
52. Centrifuge at 1300 rpm for 5 min at RT.
53. Re-suspend in 1 ml pre-warmed sterile PBS (with Ca2+ and Mg2+). Centrifuge at 1300 rpm for 5 min at RT.
54. Re-suspend in 480 µl medium supplemented with rhIL-2 and rhIL-15.
Day 1 – Application of cell suspension to placental explants
55. Collect medium from 2 wells for analysis.
56. Aspirate medium from other wells.
57. Add 10 µl cell suspension (~16,000 cells (range 4,000-42,000) to each explant.
58. Incubate for 24 h in a humidified incubator at 37°C, 21% O2.
Day 2 – Add medium
59. Add 300 µl RPMI medium with rhIL-2 and rhIL-15 to each well.
60. Incubate for 24 h in a humidified incubator at 37°C, 21% O2.
Day 3 – Change medium
61. Collect medium from 2 wells for analysis.
62. Aspirate medium from other wells.
63. Add 1 ml RPMI medium with rhIL-2 and rhIL-15 to each well.
64. Incubate for 24 h at 37°C, 21% O2, 95% humidity.
Day 4 – Harvest explants and process for assessment of placental function
65. Collect medium from two wells for analysis.
RESULTS
Trypsinization and syncytiotrophoblast morphology
A concentration of 0.01% trypsin for 15 min was found to be suffi-
cient to accelerate the shedding process without affecting the integrity 
of the villous stroma (Fig. 2).
Qualitative analysis of CK7 staining from the 96 h tissue demonstrated 
that the morphology of the explants exposed to trypsin prior to culture 
was comparable to the non-trypsinized (Fig. 3F). Additionally, System A 
activity was not considered to be irreparably affected by trypsinization. 
T cell labeling
Figure 4 illustrates that the fluorescent dyes are adequately incor-
porated into the isolated T cells.
System A activity
System A activity was unaffected by culture in IL-2 and IL-15 
supplemented medium. Figure 3 shows that system A activity over a 
60 min period remained linear and was not affected by trypsinization 
(n = 3) or culture in medium containing cytokines (n = 5) compared to 
untreated explants (controls).
Hormone secretion
Endocrine function of the STB was determined by measuring hCG 
secretion into culture medium. hCG secretion was not affected by 
pre-culture exposure of tissue fragments to trypsin (n = 4, Fig. 3C) or 
by the addition of cytokines to culture medium (n = 2, data not shown). 
Proliferation and apoptosis
Cell proliferation and apoptosis in explants after 4 days of culture 
(n = 3) was assessed using IHC with antibodies against Ki67 (prolif-
eration) and active caspase-3 (apoptosis) as previously described [30]. 
HistoQuest (TissueGnostics, Austria), unbiased image analysis software, 
was used to quantify DAB staining. DAB+ areas or events were ex-
pressed as a percentage of total haematoxylin+ areas or events. There 
was no significant difference in levels of proliferation or apoptosis in 
the trypsinized explants compared to controls (Fig. 3D and E) or the 
explants cultured in medium supplemented with cytokines compared 
to those cultured in medium alone (data not shown).
Isolated T cells
Flow cytometric analysis of the CD4 and CD8 T cells demonstrated 
that ~80-90% purity had been achieved. After 24 h in culture an aver-
age cell yield of 1.7 × 106 CD4 T cells (range 5.1 × 105–4.1 × 106) and 
1.5 × 106 CD8 T cells (4.2 × 105–3.8 × 106) was achieved. It is normal 
to encounter different proportions of CD4 and CD8 T cells between 
individuals. In our samples CD4 T cells accounted for 85-95% of those 
isolated and CD8 T cells 5–15%.
Isolated T cells in explants
In further pilot studies, fluorescence imaging was employed to as-
certain whether isolated CD4 and CD8 T cells could be located in the 
vicinity of villous tissue. This confirmed that Cell Tracker persisted for 
the 3 days that the cells were required to be in co-culture and localized 
maternal cells to the areas of the placenta associated with VUE. Figures 
4C and D show representative images of placental explants with fluo-
rescing CD4 (red) and CD8 (green) T cells in the explant. Qualitative 
analysis of the explants that were co-cultured with T cells showed 
evidence of sparse cell infiltration; T cell presence was not observed in 
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every field of view. Trypsinized explants presented areas of tissue with slightly more extensive T cell presence (Fig. 4C and D).
Figure 3. Assessment of placental function following pre-culture trypsinization and culture with cytokines interleukin (IL)-2 and IL-15 at day 
4 of culture. A. System A activity, measured as the sodium-dependent tissue accumulation of the radiolabeled substrate 14CMeAIB over time, was 
unaffected by pre-culture exposure to trypsin (mean±SE of 3 placentas), B. System A activity was unaffected by the presence of cytokines in the culture 
medium (mean±SE of 5 placentas), C. hCG secretion was not altered by pre-culture exposure to trypsin (mean±SE of 4 placentas). D-F. There was no 
significant difference in immunostaining for proliferation (Ki67) (D), apoptosis (caspase-3) (E), STB regeneration (cytokeratin 7) (F). All expressed as 
DAB+ area as a percentage of haematoxylin+ area between trypsinized and non-trypsinized explants. 
Figure 2. Representative images of pla-
cental tissue fragments stained with cy-
tokeratin 7 following incubation in trypsin 
(0.01–0.125%) for 5-30 min. When intact, 
syncytiotrophoblast staining positive for cy-
tokeratin 7 can be observed adherent to the 
villous tissue. Arrows show areas where the 
syncytiotrophoblast and villous stroma remain 
completely intact, arrowheads show areas 
where the syncytiotrophoblast layer is intact 
but has started to lift from the villous stroma 
A) Fragments incubated with 0.01% trypsin 
for 5 min. B) 0.01% trypsin for 15 min (the 
concentration used in the final protocol). C) 
0.05% trypsin for 15 min. There are areas where 
syncytiotrophoblast has completely come away 
from the villous tissue and has started to dis-
integrate. D) 0.125% trypsin for 30 min. Large 
areas of complete denudation, degeneration 
and vacuolation of syncytiotrophoblast and 
villous stroma are visible. V: villous stroma, 
MBS; maternal blood space. Scale bars rep-
resent 100 µm, original magnification ×100.
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Figure 4. Representative images of isolated CD4 and CD8 T cells. A. CD4 T cells fluorescing red after the addition of Cell Tracker CMPTX. B. CD8 
T cells fluorescing green after the addition of Cell Tracker CMFDA green. C and D. CD4 T cells (red arrows) and CD8 T cells (green arrows) in placental 
explant tissue and intervillous space at day 4 of co-culture. Nuclei are stained with DAPI. V: villous stroma, IVS: intervillous space. Dotted lines demarcate 
STB. Scale bars represent 20 µm, original magnification ×200.
DISCUSSION
The developmental work presented here has shown that it is possible 
to co-culture placental explants and T cells isolated from whole blood. 
The pilot data confirm that exposure of placental tissue to mild tryp-
sinization prior to culture does not compromise the functional capacity 
of the tissue. This was shown after examination of nutrient transport 
function via system A activity, endocrine secretion (hCG) or cellular 
kinetics (proliferation and apoptosis). In addition, the cytokines required 
to activate and stimulate proliferation of T cells (IL-2 and IL-15) do 
not adversely affect placental function. CD4 and CD8 T cells can be 
isolated, purified and fluorescently labeled, and their viability can be 
maintained for 4 days in culture. They can also be observed infiltrating 
the intervillous space and stroma of pre-trypsinized placental villous 
tissue over this time frame. 
For these validation experiments, blood from non-pregnant donors 
was used to ascertain protocol feasibility. However, in order to mimic 
VUE conditions the protocol would require the isolation of maternal 
T cells from blood. Maternal blood obtained at the time of delivery 
could be utilized, for example obtaining samples of maternal blood 
and placenta at elective Caesarean section; the timing of the protocol 
allows for this.
VUE is described as an inflammatory condition characterized by 
a villous infiltrate of fetal macrophages (Hofbauer cells; HBC) and 
maternal T cells [7,11,16,31]. It has been suggested that HBCs may 
interact with infiltrating maternal cells and thus, play a role in VUE 
[31]. We have previously shown that HBC numbers are increased in 
pregnancy pathologies such as FGR and stillbirth [15]. While individual 
variation in HBC number between placentas may influence the in vitro 
interaction or infiltration of T cells with placental tissue, this scenario 
is likely to occur in vivo as well. Critically, as there is no diagnostic 
test for VUE prior to birth, there is no means by which VUE, CIUE or 
numbers of HBCs can be evaluated in a sufficiently timely manner to 
allow functional experiments to be conducted on placental samples. An 
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alternative approach would be to conduct functional experiments on 
unselected placental samples and subsequently to analyze their results by 
VUE status after a diagnosis has been made. However, as the incidence 
of VUE at term is estimated at 12%, 8-fold more experiments would be 
required, thus such an approach is unrealistic. Both these observations 
support the need for the development of in vitro models of placental 
inflammation to understand its functional consequences.
Our novel experimental data provides a working model on which 
to base co-culture studies to explore the mechanisms by which T cell 
infiltration could cause placental dysfunction in VUE. However, the 
use of this model could be advocated for a broader spectrum of exper-
imental conditions including CIUE, diabetes-induced inflammation 
and autoimmune conditions such as systemic lupus erythematosus. 
The role of a range of specific leukocytes in inflammatory conditions 
could be examined as could the mechanism by which tolerance of a 
pregnancy is achieved. 
TROUBLESHOOTING
The preliminary studies carried out to design this protocol used blood 
from non-pregnant donors. For experiments to examine the mechanics 
of VUE, placenta and maternal blood from the same pregnancy would 
be used. On day 0 if the placenta and blood samples arrive at the labo-
ratory at the same time, processing of the placenta should take priority 
as its functional capacity depletes in a shorter time frame.
If Cell Tracker cytoplasmic fluorescence fails, ensure that the vials 
have been protected from light during storage. 
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